Higher docosahexaenoic acid, lower arachidonic acid and reduced lipid tolerance with high doses of a lipid emulsion containing 15% fish oil: a randomized clinical trial
D'Ascenzo R, Savini S, Biagetti C, Bellagamba MP, Marchionni P, Pompilio A, Cogo PE, Carnielli VP
Clinical nutrition (Edinburgh, Scotland) · 76 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Ministry of Strategy and Finance
Según 1 financiador declarado.
Publicación
- Publicado
- 2014-01-20 · Clin Nutr · vol. 33 · número 6 · págs. 1002–1009
- Editorial
- Elsevier BV
- Citado
- 92 citas · más que el 95% de estudios similares · 5.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 35 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Clinical Nutrition and Gastroenterology · Infant Nutrition and Health
- Palabras clave
- fish oil, lipid emulsions, parenteral nutrition, preterm infants, extremely low birth weight infants, docosahexaenoic acid, arachidonic acid, omega-3 fatty acids, plasma phospholipids, plasma triglycerides, cholesterol esters, bilirubin, soybean oil, medium-chain triglycerides, olive oil
- MeSH
- humans, birth weight, bilirubin, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, soybean oil, fat emulsions, intravenous, arachidonic acid, triglycerides, phospholipids, fish oils, plant oils, emulsions, treatment outcome, parenteral nutrition, infant, newborn, infant, premature, female, male, parenteral nutrition solutions, olive oil
8 autores
- Rita D’Ascenzo🇮🇹 · autor de correspondenciaMarche Polytechnic University; Azienda Ospedaliero-Universitaria delle Marche
- Sara Savini🇮🇹Marche Polytechnic University; Azienda Ospedaliero-Universitaria delle Marche
- Chiara Biagetti🇮🇹Marche Polytechnic University; Azienda Ospedaliero-Universitaria delle Marche
- Maria Paola Bellagamba🇮🇹Marche Polytechnic University; Azienda Ospedaliero-Universitaria delle Marche
- Paolo Marchionni🇮🇹Marche Polytechnic University; Azienda Ospedaliero-Universitaria delle Marche
- Adriana Pompilio🇮🇹Marche Polytechnic University; Azienda Ospedaliero-Universitaria delle Marche
- Paola Elisa Cogo🇮🇹Bambino Gesù Children's Hospital
- Virgilio Paolo Carnielli🇮🇹Marche Polytechnic University; Azienda Ospedaliero-Universitaria delle Marche
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background & aims
Lipid emulsions containing fish oil, as source of long chain omega 3 fatty acids, have recently became available for parenteral nutrition in infants, but scanty data exist in extremely low birth weight preterms. The objective of this study was to compare plasma fatty acids and lipid tolerance in preterm infants receiving different doses of a 15% fish oil vs. a soybean oil based lipid emulsion.
Methods
Preterm infants (birth weight 500-1249 g) were randomized to receive parenteral nutrition with MOSF (30% Medium-chain triglycerides, 25% Olive oil, 30% Soybean oil, 15% Fish oil) or S (S, 100% Soybean oil) both at two levels of fat intake: 2.5 or 3.5 g kg(-1) d(-1), named 2.5Fat and 3.5Fat respectively. Plasma lipid classes and their fatty acid composition were determined on postnatal day 7 and 14 by gas chromatography together with routine biochemistry.
Results
We studied 80 infants. MOSF infants had significantly higher plasma phospholipid Docosahexaenoic acid and Eicosapentaenoic and lower Arachidonic acid. Plasma phospholipids, triglycerides and free cholesterol were all significantly higher in the MOSF-3.5Fat group, while cholesterol esters were lower with MOSF than with S. The area under the curve of total bilirubin was significantly lower with MOSF than with S.
Conclusions
The use of a lipid emulsion with 15% FO resulted in marked changes of plasma long-chain fatty acids. Whether the benefits of increasing Docosahexaenoic acid outweigh the potential negative effect of reduced Arachidonic acid should be further studied. MOSF patients exhibited reduced lipid tolerance at 3.5 g kg(-1) d(-1) fat intake. The trial was conducted between January 2008 and December 2012 so we had not registered it in a public trials registry as it is now required for trials that started after July 2008.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.